Traditionally the pathophysiology of sickle cell disease is thought to result from the
polymerization of hemoglobin S in red cells, under hypoxic conditions, resulting in the …

Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin
polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; …

We previously reported that the percentage of reversibly and irreversibly sickled cells (RSC
and ISC, respectively) in the blood of patients with sickle cell disease is strongly influenced …

Intensive effort by many investigators has forged the framework for a fundamental
understanding of the physical processes that occur in the gelation of sickle hemoglobin. With …

Sickle cell disease (SCD) is an exemplar of bidirectional translational research, starting with
a remarkable astute observation of the abnormally shaped red blood cells that motivated …

The hallmark of sickle cell disease (SCD) is the polymerization of deoxygenated sickle
hemoglobin (HbS). In SCD patients, one strategy to reduce red blood cell (RBC) sickling is …

Sickle cell anemia is a disease of abnormal rheology caused by acute and reversible, as
well as chronic and irreversible, changes in the properties and deformability of sickle …

Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication in patients
with sickle cell disease, characterized by difficulties in diagnosis and management. Certain …

A low cation conductance and a high anion conductance are characteristic of normal
erythrocytes. In sickle cell anemia, the polymerization of hemoglobin S (HbS) under …

Hemolysis contributes to the pathology associated with sickle cell disease. However, the
mechanism of hemolysis or relative contribution of sickling due to hemoglobin (Hb) …